Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...
News Medical on MSN5d
Study highlights potential of genomic tests for early stage prostate cancerA new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...
Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...
A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...
For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk ...
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...
Prolaris, or the Oncotype DX Genomic Prostate Score (GPS), very low- or low-risk patients with prostate cancer were more likely to have their risk levels classified as the same or lower (GPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback